Eli Lilly completes $1.04bn acquisition of Prevail Therapeutics to expand gene therapy program
Eli Lilly and Company has officially finalized its acquisition of Prevail Therapeutics in a deal valued at up to $1.04 billion. This acquisition represents a ... Read More
Eli Lilly to acquire Prevail Therapeutics for $1.04bn, expanding gene therapy pipeline
Eli Lilly and Company has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a prominent US gene therapy company specializing in ... Read More
Janssen acquires HMR59 from Hemera for geographic atrophy treatment
Janssen Pharmaceuticals has secured the rights to an innovative gene therapy, HMR59, for the treatment of geographic atrophy, a severe form of age-related macular degeneration ... Read More
Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round
California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 ... Read More
Roche signs $2.85bn deal with Sarepta for SRP-9001 DND gene therapy
Roche has signed a licensing deal worth up to $2.85 billion with Sarepta Therapeutics for the exclusive ex-US commercial rights to the latter’s SRP-9001 (AAVrh74.MHCK7.micro-dystrophin), ... Read More
Astellas Pharma to acquire US gene therapy company Audentes Therapeutics
Astellas acquisition of Audentes: Japanese pharma company Astellas Pharma has agreed to acquire US gene therapy company Audentes Therapeutics in an all-cash deal worth about ... Read More
Ferring, Blackstone invest $570m in nadofaragene firadenovec gene therapy
Ferring Pharmaceuticals, a Swiss specialty biopharmaceutical group, has teamed up with private investment platform Blackstone Life Sciences to jointly invest more than $570 million in ... Read More
Cellectis begins MELANI-01 clinical trial for UCARTCS1 in multiple myeloma
Cellectis said that it has dosed the first patient in a phase 1 study - the MELANI-01 clinical trial to evaluate UCARTCS1, an allogeneic off-the-shelf ... Read More
Avrobio gets FDA orphan status for AVR-RD-02 in Gaucher disease
US gene therapy company Avrobio has secured orphan-drug designation for AVR-RD-02, its investigational gene therapy, for the treatment of Gaucher disease, from the US Food ... Read More
4D Molecular Therapeutics secures $90m in Series B to advance gene therapy innovations
California-based 4D Molecular Therapeutics (4DMT), specializing in adeno-associated virus (AAV) gene therapy vector discovery and product development, has successfully raised $90 million through a Series ... Read More